Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of continuous versus intermittent vemurafenib + cobimetinib in BRAF V600–mutant metastatic melanoma
2014-005277-36Phase 2Completed
- Sponsor
- Gem
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vemurafenib and cobimetinib in melanoma (2 arms), sponsored by Gem. Primary endpoint: Progression-free survival. Started Jan 2015; status: completed.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-005277-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005277-36.